Literature DB >> 26687450

Overexpression of NAD(P)H:quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones.

Christophe Glorieux1, Juan Marcelo Sandoval1, Nicolas Dejeans1, Geneviève Ameye2, Hélène Antoine Poirel2, Julien Verrax1, Pedro Buc Calderon3.   

Abstract

AIMS: Alterations in the expression of antioxidant enzymes are associated with changes in cancer cell sensitivity to chemotherapeutic drugs (menadione and β-lapachone). Mechanisms of acquisition of resistance to pro-oxidant drugs were investigated using a model of oxidative stress-resistant MCF-7 breast cancer cells (Resox cells). MAIN
METHODS: FISH experiments were performed in tumor biopsy and breast cancer cells to characterize the pattern of the NQO1 gene. SNP-arrays were conducted to detect chromosomal imbalances. Finally, the importance of NQO1 overexpression in the putative acquisition of either drug resistance or an increased sensitivity to quinones by cancer cells was investigated by immunoblotting and cytotoxicity assays. KEY
FINDINGS: Genomic gain of the chromosomal band 16q22 was detected in Resox cells compared to parental breast cancer MCF-7 cells and normal human mammary epithelial 250MK cells. This genomic gain was associated with amplification of the NQO1 gene in one tumor biopsy as well as in breast cancer cell lines. Using different breast cell models, we found that NQO1 overexpression was a main determinant for a potential chemotherapy resistance or an increased sensitivity to quinone-bearing compounds. SIGNIFICANCE: Because NQO1 is frequently modified in tumors at genomic and transcriptomic levels, the impact of NQO1 modulation on breast cancer cell sensitivity places NQO1 as a potential link between cancer redox alterations and resistance to chemotherapy. Thus, the NQO1 gene copy number and NQO1 activity should be considered when quinone-bearing molecules are being utilized as potential drugs against breast tumors.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer cells; Genomic gain; Menadione; NQO1; Redox alterations; β-Lapachone

Mesh:

Substances:

Year:  2015        PMID: 26687450     DOI: 10.1016/j.lfs.2015.12.017

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  13 in total

1.  Lentiviral-Mediated Netrin-1 Overexpression Improves Motor and Sensory Functions in SCT Rats Associated with SYP and GAP-43 Expressions.

Authors:  Xue Fei Han; Yuan Zhang; Liu Lin Xiong; Yang Xu; Piao Zhang; Qing Jie Xia; Ting Hua Wang; Ying Chun Ba
Journal:  Mol Neurobiol       Date:  2016-02-12       Impact factor: 5.590

2.  Kinetics of Glutathione Depletion and Antioxidant Gene Expression as Indicators of Chemical Modes of Action Assessed in Vitro in Mouse Hepatocytes with Enhanced Glutathione Synthesis.

Authors:  Fjodor Melnikov; Dianne Botta; Collin C White; Stefanie C Schmuck; Matthew Winfough; Christopher M Schaupp; Evan P Gallagher; Bryan W Brooks; Edward Spencer Williams; Philip Coish; Paul T Anastas; Adelina Voutchkova-Kostal; Jakub Kostal; Terrance J Kavanagh
Journal:  Chem Res Toxicol       Date:  2019-01-07       Impact factor: 3.739

3.  Detection of DT-diaphorase Enzyme with a ParaCEST MRI Contrast Agent.

Authors:  Iman Daryaei; Kyle M Jones; Mark D Pagel
Journal:  Chemistry       Date:  2017-04-20       Impact factor: 5.236

4.  Profiling the chemical nature of anti-oxytotic/ferroptotic compounds with phenotypic screening.

Authors:  David Soriano-Castell; Zhibin Liang; Pamela Maher; Antonio Currais
Journal:  Free Radic Biol Med       Date:  2021-11-05       Impact factor: 7.376

Review 5.  Azoreductases in drug metabolism.

Authors:  Ali Ryan
Journal:  Br J Pharmacol       Date:  2016-09-02       Impact factor: 8.739

6.  Apoptosis inducing factor (AIF) mediates lethal redox stress induced by menadione.

Authors:  Hesti Lina Wiraswati; Emilie Hangen; Ana Belén Sanz; Ngoc-Vy Lam; Camille Reinhardt; Allan Sauvat; Ariane Mogha; Alberto Ortiz; Guido Kroemer; Nazanine Modjtahedi
Journal:  Oncotarget       Date:  2016-11-22

7.  Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.

Authors:  Marco Fiorillo; Federica Sotgia; Diego Sisci; Anna Rita Cappello; Michael P Lisanti
Journal:  Oncotarget       Date:  2017-03-02

8.  Catalase down-regulation in cancer cells exposed to arsenic trioxide is involved in their increased sensitivity to a pro-oxidant treatment.

Authors:  Christophe Glorieux; Pedro Buc Calderon
Journal:  Cancer Cell Int       Date:  2018-02-20       Impact factor: 5.722

9.  Evaluation of Potential Mechanisms Controlling the Catalase Expression in Breast Cancer Cells.

Authors:  Christophe Glorieux; Juan Marcelo Sandoval; Nicolas Dejeans; Sandrine Nonckreman; Khadija Bahloula; Hélène A Poirel; Pedro Buc Calderon
Journal:  Oxid Med Cell Longev       Date:  2018-01-28       Impact factor: 6.543

10.  Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistance.

Authors:  Onat Kadioglu; Jingming Cao; Nadezda Kosyakova; Kristin Mrasek; Thomas Liehr; Thomas Efferth
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.